Within small-animal dermatology practice, ketoconazole API for oral tablet manufacture is directed toward systemic therapy of Microsporum canis, Trichophyton spp., and Malassezia pachydermatis infections in dogs and cats. The compliance framework includes EU Regulation (EU) 2019/6 for veterinary medicinal products, VICH GL18(R2) for residual solvents, ICH Q3D for elemental impurities, Ph. Eur. 2.6.12/2.6.13 for non-sterile microbial quality, and USP <905> for content uniformity. Tablets are intended for non-food companion animals only; no maximum residue limit is established for food-producing species. The addition ratio is determined by tablet core mass and target dose: a 200 mg ketoconazole tablet with a 400 mg core corresponds to 50% w/w active load, while a 50 mg tablet in the same 400 mg core corresponds to 12.5% w/w; typical wet-granulated cores therefore operate between 12.5% w/w and 50% w/w, the lower bound controlled by content uniformity data and the upper bound by granule flow and tablet hardness. The downstream process uses high-shear wet granulation: ketoconazole is pre-blended with lactose monohydrate and povidone K30 in a 65 L high-shear granulator, wet-massed with purified water, wet-milled through a 1.5 mm screen, dried in a fluid-bed dryer at inlet air 55–65 °C to loss on drying ≤ 2.0% w/w, then lubricated with magnesium stearate and compressed on a rotary tablet press at 8–12 kN compression force. Dissolution is controlled using USP <711> apparatus II in 0.1 N hydrochloric acid because ketoconazole exhibits pH-dependent solubility; tablets are film-coated to reduce esophageal irritation. Finished dosage forms include immediate-release veterinary tablets in 50 mg, 100 mg, and 200 mg strengths supplied as unit-dose blister packs or bulk clinic packs.

What Limits Capsule-Filling Uniformity in Low-Dose Feline and Avian Ketoconazole Therapy?

In feline and avian medicine, hard gelatin capsules allow dose titration below commercially available tablet strengths, but low-dose ketoconazole capsule production is controlled by powder flow, particle size distribution, and fill mass variability. Compliance requires Ph. Eur. 2.9.40 for uniformity of dosage units of powders and liquids for oral use, USP <905> for content uniformity, VICH GL18(R2) for residual solvents, ICH Q3D for elemental impurities, and Ph. Eur. 2.6.12/2.6.13 for non-sterile microbial quality. The addition ratios are calculated from the target fill mass: a 50 mg feline capsule with a 200 mg total fill mass corresponds to 25% w/w API; a 20 mg avian capsule with a 160 mg total fill mass corresponds to 12.5% w/w API; these ratios require geometric dilution because direct blending at low load can produce segregation and content uniformity failures. The downstream process uses a low-shear tumble blender with intensifier bar, with ketoconazole first milled through a 0.5 mm screen and pre-blended 1:1 with lactose monohydrate, then combined with microcrystalline cellulose and croscarmellose sodium; final fill weight is controlled at ±3% target on a dosator-type capsule filling machine. Dissolution testing in 0.1 N hydrochloric acid per USP <711> demonstrates pH-sensitive release. Finished product types include hard gelatin capsules in 20 mg, 25 mg, 50 mg, and 100 mg strengths for non-food companion and avian patients, supplied in HDPE bottles with desiccant and tamper-evident closures.

For in-clinic dose adjustment in patients unable to accept solid oral dosage forms, ketoconazole oral powder is manufactured as a preservative-free dry blend for reconstitution into an aqueous suspension or direct mixing with food. Compliance is established through Ph. Eur. 2.6.12/2.6.13 for non-sterile microbial limits, VICH GL18(R2) for residual solvents, ICH Q3D for elemental impurities, and EU GMP Part I for finished dosage form manufacture; because reconstituted powder is used within 7 days at 2–8 °C, sterility is not required. The addition ratio is calculated from sachet fill mass: a 1 g sachet containing 100 mg ketoconazole corresponds to 10% w/w API; a 2 g sachet containing 200 mg also corresponds to 10% w/w API; after reconstitution with 20 mL purified water, the nominal concentration is 5 mg/mL. The downstream process consists of low-shear dry blending in a bin blender at 6 rpm for 15 minutes, with the blend filled into single-dose sachets under relative humidity below 40% to prevent moisture uptake. Finished product types include 100 mg and 200 mg oral powder sachets for dogs, cats, and non-food exotic patients, supplied in aluminum foil laminate sachets.

Granule Flow, Friability, and Acid-Mediated Release in Captive Wildlife Formulations

Ketoconazole granules for non-food captive wildlife patients are produced by wet granulation or extrusion-spheronization to provide dose flexibility for feed top-dress or gastric tube administration. The relevant standards are Ph. Eur. 2.6.12/2.6.13 for non-sterile microbial quality, VICH GL18(R2) for residual solvents, ICH Q3D for elemental impurities, Ph. Eur. 2.9.3 for dissolution of solid oral dosage forms, and EU GMP Part I for manufacture. The API loading in the granule for a 500 mg dose unit containing 50 mg ketoconazole is 10% w/w; if diluted into a 20 g feed top-dress, the active concentration becomes 0.25% w/w; typical granule formulations contain 5–15% w/w API depending on the target dose unit mass and carrier capacity. The downstream process uses fluid-bed top-spray granulation with an aqueous binder solution, or low-shear wet granulation followed by extrusion spheronization; granules are screened to 710–1400 µm after drying to a loss on drying ≤ 2.0% w/w, and friability is controlled by granule hardness and moisture content. Dissolution testing is performed in 0.1 N hydrochloric acid at 37 °C according to USP <711> apparatus II, with sampling at 15, 30, and 45 minutes to confirm acid-mediated release. Finished product types include bulk granules in 500 mg unit sachets and 100 g containers for zoo, wildlife, and exotic animal veterinary use.

When Aqueous Solubility of Ketoconazole Restricts Oral Solution Manufacture

Ketoconazole is practically insoluble in neutral and alkaline aqueous media, so oral solution manufacture is restricted to acidified vehicles that maintain the API in solution at the target concentration. The applicable controls are Ph. Eur. 2.6.12/2.6.13 for non-sterile microbial quality, VICH GL18(R2) for residual solvents, ICH Q3D for elemental impurities, and EU Regulation (EU) 2019/6 for finished veterinary medicinal products. For a target concentration of 10 mg/mL, the required addition ratio is 1% w/v ketoconazole, with pH adjusted to 2.5–3.5 using hydrochloric acid or citric acid buffer; the vehicle may contain propylene glycol as a cosolvent, and oxygen-sensitive formulations require nitrogen sparging to limit oxidative discoloration. The downstream process is a sequential dissolution operation: ketoconazole is dissolved in acidified purified water at 20–25 °C under high-shear mixing, the pH is re-checked after API addition, the solution is filtered through a 0.2 µm membrane, filled into amber Type III glass bottles under nitrogen, and sealed with child-resistant closures. Finished product types include 10 mg/mL oral solution in 30 mL and 100 mL bottles for dogs, cats, and non-food exotic species; storage below 25 °C is specified because precipitation can occur if the solution is diluted into neutral media or stored above pH 3.5.

A 2% w/w Ketoconazole Ointment Is Processed by Melt Dispersion, Not Aqueous Gelation

Topical ketoconazole veterinary ointment is produced as an anhydrous or low-moisture dosage form for localized treatment of Malassezia dermatitis and dermatophytosis in companion animals. Quality requirements are set by Ph. Eur. 2.6.12/2.6.13 for non-sterile microbial quality, VICH GL18(R2) for residual solvents, ICH Q3D for elemental impurities, and EU Regulation (EU) 2019/6 for finished veterinary medicinal products; if the ointment contains no water, preservative effectiveness testing under USP <51> is not required. The final concentration in the hydrophobic oleaginous base is 2% w/w ketoconazole (20 mg/g), typically in white petrolatum with mineral oil and microcrystalline wax; higher loadings are avoided because ketoconazole particles can agglomerate during cooling. The downstream process uses melt dispersion: the base components are heated to 70–75 °C, ketoconazole is levigated with a portion of mineral oil to form a particle slurry, the slurry is added to the molten base under high-shear dispersion, and the mixture is cooled to 40 °C with continuous low-shear agitation before filling into aluminum or laminate tubes. Finished product types include 2% w/w ketoconazole ointment in 15 g, 30 g, and 60 g tubes for veterinary use in dogs and cats.

Why Are Maximum Residue Limits the Binding Constraint in Ketoconazole Premix Applications?

Ketoconazole premixes are manufactured for oral administration to non-food-producing species in zoological and shelter settings; these premixes are not intended for livestock or any food-producing animal because maximum residue limits are not established. The compliance chain includes EU Regulation (EU) 2019/6 for veterinary medicinal products, VICH GL18(R2) for residual solvents, ICH Q3D for elemental impurities, ICH Q7 for GMP in active pharmaceutical ingredient and premix manufacture, and feed hygiene controls for carrier handling. Premix active concentration is defined by the final blend: a 2% w/w premix (20 mg/g) is typically diluted at 1:20 in feed to yield 1 mg/g final feed; inclusion rates range from 0.5% w/w to 5.0% w/w depending on carrier type, dust generation, and target dose. The downstream process uses a ribbon blender to mix ketoconazole with a lactose or microcrystalline cellulose carrier, after which the blend is filled into multi-wall paper bags with polyethylene liners; dust control and line clearance are required because of cross-contamination risk in multiproduct facilities. Finished product types include 1 kg, 5 kg, and 25 kg premix bags labeled for non-food animal use only.

Parenteral Ketoconazole Is Compounded Under Aseptic Constraints Rather Than Terminal Sterilization

Parenteral ketoconazole use in veterinary medicine is restricted to extemporaneous sterile compounding in hospital settings because no harmonized pharmacopoeial monograph for ketoconazole injection exists. Compliance for such preparations must include Ph. Eur. 2.6.1 for sterility, Ph. Eur. 2.6.14 for bacterial endotoxins, ICH Q3D for elemental impurities, and EU GMP Annex 1 for sterile manufacture where applicable. The compounding formula uses 0.5% w/v ketoconazole for a 5 mg/mL injection, dissolved in an acidified aqueous vehicle at pH 2.0–3.5; precipitation upon neutral pH is the critical process failure mode, so sulfobutylether-β-cyclodextrin is used in some hospital formulations to improve solubility and reduce precipitation risk. The downstream process requires dissolution under aseptic conditions, filtration through a 0.22 µm sterilizing filter, and filling into sealed Type I glass vials; terminal steam sterilization is generally not applied because of pH-dependent degradation and precipitation risk. Finished product types are limited to patient-specific compounded vials at 5 mg/mL; published data for commercial-scale ketoconazole injection is limited.